Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Nile completes dosing in CD-NP Phase II study for acute decompensated heart failure

Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The study was designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with ADHF and mild to moderate renal insufficiency.

7 Jul 2010

Researchers identify key players in biochemical pathway that regulates blood pressure

Researchers at the University of Pittsburgh School of Medicine have identified key players in a little-known biochemical pathway that appears to regulate blood pressure. The findings, reported in the early online version of Cardiovascular Research, have evolved from studies conducted by Jeffrey S. Isenberg, M.D., Eileen M. Bauer, Ph.D., and their colleagues at Pitt's Vascular Medicine Institute.

7 Jul 2010

ASPREE study aims to assess health benefits of aspirin

In an effort to extend the length of a disability-free life for older adults, researchers from Rush University Medical Center are partnering with colleagues from across the U.S. and Australia in the largest international trial ever sponsored by the National Institute on Aging.

7 Jul 2010

Experts show the continuing global impact of Framingham Heart Study

Few medical investigations have had the impact of the Framingham Heart Study. This study, started in 1948, was designed as a cohort, observational study of cardiovascular disease, then recognized as a growing health threat but now has emerged as much more. The Framingham Heart study came to revolutionize thinking about cardiovascular disease, change the study of epidemiology, and even force the biostatistics community to develop multivariate analysis.

7 Jul 2010

Pfizer's new chewable Lipitor for children receives European Commission approval

Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor.

7 Jul 2010

St. Jude Medical acquires LightLab Imaging

St. Jude Medical, Inc., a global medical device company, today completed the previously announced acquisition of LightLab Imaging, Inc. for approximately $90 million in cash.

7 Jul 2010

The heart and the psyche – Link between heart disease and anxiety-depressive disorders

According to a new report published in the acclaimed journal Archives of General Psychiatry, concomitant anxiety and other psychiatric illnesses in heart patients raise their risk of getting heart attacks, strokes, heart failure and early death.

5 Jul 2010

Quintiles announces strategic alliance agreement with UMMC as part of Prime Site program

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University Malaya Medical Centre as part of its unique Prime Site program - an initiative focused on accelerating the development of new and more effective medicines.

5 Jul 2010

Exposure to carbon monoxide, air pollution does not increase preterm delivery risk

While pregnant women may worry about the effects of air pollution on their health and that of their developing child, exposure to carbon monoxide and fine particles in the air during pregnancy does not appear to increase the risk of preterm delivery or preeclampsia -- a serious condition that arises only during pregnancy -- according to results of a study headed by a University at Buffalo epidemiologist.

2 Jul 2010

Vitamin D inadequacy may cause metabolic syndrome among elderly people

A new study adds to the mounting evidence that older adults commonly have low vitamin D levels and that vitamin D inadequacy may be a risk factor for the metabolic syndrome, a condition that affects one in four adults. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Older men with high testosterone levels more likely to have heart attacks

A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

Preliminary results of a pre-specified subgroup study analysis of patients with diabetes and hypertension demonstrated that the investigational triple combination therapy of olmesartan medoxomil / amlodipine / hydrochlorothiazide (40/10/25 mg) resulted in a statistically significant greater Least Squares mean reduction in blood pressure from baseline at week 12 (37.9/22.0 mm Hg versus 26.4-28.0/14.7-17.6 mm Hg, P less than or equal to 0.0013) as compared to corresponding dual combination therapy [olmesartan medoxomil (40 mg) / amlodipine (10 mg); olmesartan medoxomil (40 mg) / hydrochlorothiazide (25 mg); or amlodipine (10 mg) and hydrochlorothiazide (25 mg)].

1 Jul 2010

Olive oil, Mediterranean diet modify expression of atherosclerosis-related genes

Everyone knows olive oil and a Mediterranean diet are associated with a lower risk for cardiovascular disease, but a new research report published in the July 2010 print issue of the FASEB Journal offers a surprising reason why: These foods change how genes associated with atherosclerosis function.

1 Jul 2010

ESMT CA study: Cutting pharmaceutical prices will reduce number of new medications

Cutting pharmaceutical prices will severely reduce the number of new medications making it to market, according to a groundbreaking independent study from ESMT Competition Analysis. For the first time, the study on 'Pharmaceutical Innovation and Pricing Regulation' clearly models and quantifies the direct link between strict regulation and low innovation.

1 Jul 2010

Researchers report no increased rate of heart attack in patients taking rosiglitazone

The diabetes drug rosiglitazone has been under intense scrutiny since a 2007 study in the New England Journal of Medicine looked at more than 40 clinical trials and linked the drug's use with increased risk of heart attack and death from heart disease.

1 Jul 2010

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.

1 Jul 2010

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that it has reached the enrollment goal of 325 patients for its Phase 2b dose-ranging clinical trial of XOMA 052, and that it expects patient enrollment to close in July 2010, with top-line results available in the first quarter of 2011. XOMA 052 is a therapeutic antibody candidate that inhibits the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta) which drives the inflammatory cause of Type 2 diabetes.

1 Jul 2010

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

The Washington Post: Two new studies provide evidence "that the diabetes drug Avandia increases the risk of heart problems and strokes, renewing questions about the safety of the medication. ... The new research, released Monday, should prompt the Food and Drug Administration to remove the drug from the market, according to the researchers who led the analyses and several drug-safety advocates.

30 Jun 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Nile completes dosing in CD-NP Phase II study for acute decompensated heart failure

Researchers identify key players in biochemical pathway that regulates blood pressure

ASPREE study aims to assess health benefits of aspirin

Experts show the continuing global impact of Framingham Heart Study

Pfizer's new chewable Lipitor for children receives European Commission approval

St. Jude Medical acquires LightLab Imaging

The heart and the psyche – Link between heart disease and anxiety-depressive disorders

Quintiles announces strategic alliance agreement with UMMC as part of Prime Site program

Exposure to carbon monoxide, air pollution does not increase preterm delivery risk

Vitamin D inadequacy may cause metabolic syndrome among elderly people

Older men with high testosterone levels more likely to have heart attacks

Study results of triple combination therapy in patients with diabetes and hypertension presented at ADA 2010

Olive oil, Mediterranean diet modify expression of atherosclerosis-related genes

ESMT CA study: Cutting pharmaceutical prices will reduce number of new medications

Researchers report no increased rate of heart attack in patients taking rosiglitazone

Sepracor announces preliminary results from OMNARIS HFA Phase III study for seasonal allergic rhinitis

XOMA reaches enrollment goal of 325 patients for Phase 2b clinical trial of XOMA 052

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study highlights importance of individualized, patient-centered therapies

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Newsletters you may be interested in